VLRL News

Valar Labs’ CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer

VLRL

PALO ALTO, Calif.--(BUSINESS WIRE)--Valar Labs publishes new evidence in European Urology validating CHAI biomarkers for risk stratification of recurrence and progression